🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesEchocardiographic changes on GLP-1 — November 2025

Echocardiographic changes on GLP-1 — November 2025

NeuroNate Sat, Mar 14, 2026 at 8:34 PM 29 replies 1,138 viewsPage 1 of 6
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Mar 14, 2026 at 8:34 PM#1

My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

What I actually want to know is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Tell me what I have not thought of.

36 14jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 33 others
Reply Quote Save Share Report
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Mar 14, 2026 at 8:45 PM#2
NeuroNate said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

References:
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
Last edited: Mar 15, 2026 at 2:45 AM
37 15Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 34 others
Reply Quote Save Share Report
rachel_ABQ
Member
178
890
Dec 2024
Albuquerque, NM
Mar 14, 2026 at 8:56 PM#3
Dr.CardioMD said:
I want to bring up the cardiovascular angle on cardiovascular risk.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.1 lbs/week average
Fasting glucose (finger stick): stable at 82 mg/dL
Blood pressure (home): 116/72 average
Resting heart rate: 62 bpm (down from 78)
Waist circumference: down 12 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

38 16AmyNC_wife, SkepticalSean, Dr.CardioMD and 35 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Mar 14, 2026 at 9:07 PM#4
NeuroNate said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Mine went the same way, slower. The detail I would add is minor and it is already implied above.

Last edited: Mar 15, 2026 at 2:07 AM
39 17julia.endo, JessicaM_2024, TomFromTexas and 36 others
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Mar 14, 2026 at 10:06 PM#5

From the other side of the consultation, briefly.

I'm 62 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

14 months later: down 61 lbs, off atorvastatin, A1C from 8.2% to 5.4%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Mar 15, 2026 at 1:06 AM
40 18LarryQC_SD, wanda_boise, NurseAsh_DET and 37 others
Reply Quote Save Share Report
1236

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register